Roger Pomerantz, ContraFect CEO (via X-Vax)
Blaming placebo response for 'uninterpretable' PhIII results, ContraFect calls for new antibiotic study
Having spent the past few months combing through the data from a Phase III trial that it stopped for futility, ContraFect concluded that it still …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
